Search | Clinical Trials Finder

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions: [225]-FPI-2059, [111In]-FPI-2058; Drug
Lead sponsor: 3B Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more

Conditions: Solid Tumors, Breast Cancer
Interventions: AT13387; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Lymphoma
Interventions: Aspiration, Biospecimen Collection, Catheterization, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Glargine, LY2189265, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 36
States / cities: Concord, California • La Mesa, California • Lancaster, California + 33 more

Conditions: Renal Cell Carcinoma
Interventions: Arterial Spin Labeling Magnetic Resonance Imaging; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tumors With CDK4/6 Pathway Activation
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 61
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more

Conditions: Pancreatic Adenocarcinoma
Interventions: Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery, Milestone 3: Chemoradiotherapy (cXRT), Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery, Milestone 4: Chemoradiotherapy (cXRT), Milestone 5: Targeted chemotherapy after surgery, Milestone 5: Chemoradiotherapy (cXRT), Milestone 6: Gemcitabine after surgery, Milestone 6: Chemoradiotherapy (cXRT), Milestone 7: Chemoradiotherapy (cXRT), Milestone 8: Targeted chemotherapy after surgery, Milestone 9: Gemcitabine after surgery, Milestone 10: No additional therapy after surgery; Drug · Radiation · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Conditions: Treatment Resistant Depression
Interventions: FEAST, FEAST RP; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 22 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetic Retinopathy
Interventions: blood draw; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 98 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Everolimus, MLN0128, MLN1117; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 7
States / cities: Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more

Conditions: Thyroid Disease
Interventions: SPECT; Radiation
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, radiation therapy; Drug · Radiation
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Preterm Infants, Respiratory Distress Syndrome (Neonatal), BPD - Bronchopulmonary Dysplasia
Interventions: Pressure Targeted High Flow, CPAP; Procedure
Lead sponsor: University of Texas at Austin; Other
Eligibility: 7 Days to 40 Weeks
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Diego, California • Austin, Texas

Conditions: Non Small Cell Lung Cancer, CNS Progression
Interventions: Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Relapsed Refractory Multiple Myeloma
Interventions: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 48
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 40 more

Conditions: Chronic Pain, Tobacco Use, Opioid Substitution Treatment
Interventions: Very Low Nicotine Cigarettes (VLNC), Normal Nicotine Cigarettes (NNC); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Unresectable or Metastatic Solid Malignancy
Interventions: Entrectinib, Inavolisib, Alectinib, Ipatasertib, Atezolizumab, Trastuzumab Emtansine, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Tucatinib, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, Pralsetinib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 38
States / cities: Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more

Conditions: Sleep Apnea Syndromes
Interventions: Continuous positive airway pressure; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
Interventions: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV; Radiation
Lead sponsor: Ayal A. Aizer, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions: Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Spinal Cord Injuries, Endothelial Dysfunction
Interventions: Intra-arterial Infusion of Vasoactive Agents, Intra-arterial Vitamin C Infusion, Blood Sampling; Procedure
Lead sponsor: Craig Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 192
States / cities: Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more

Search by objective public record fields.

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

AT13387 in Adults With Refractory Solid Tumors

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Enhanced Spatial Targeting in ECT Utilizing FEAST

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing

Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer

Pressure Targeting During High Flow Therapy in Premature Infants

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Opioids, Low Nicotine Cigarettes, and Chronic Pain

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Race And CPAP Effectiveness

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Acceptance and Commitment Therapy Principles for Diabetes Prevention

Endothelial Dysfunction After SCI

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)